Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Families and children news

Show

From To
Efavirenz in HIV-positive pregnant women, risk of neurological condition in children

Researchers found children of women whose ART regimen included efavirenz were 60 percent more likely to develop a neurological condition, such as microcephaly (small head), seizures (from a high fever or other cause) and eye abnormalities than children whose mothers took other ART medications.

Published
05 October 2018
From
IDSA press release
Sexual Health, Reproductive Health & HIV Policy eBulletin - September 2018

The September issue of the Sexual Health & HIV Policy E-bulletin is available to read online. This issue covers the announcement by the Department of Health and Social Care to allow women to take misoprostol at home in England; a new audit on cuts to contraceptive services; and an e-feature on sex education in schools.

Published
28 September 2018
From
FSRH
Access to on-the-spot testing led to improved rates of treatment for infants with HIV

Tests to detect HIV in infants conducted at health facilities where they received care led to a significant increase in the percentage of infants with the virus given access to life-saving treatment, compared to tests analyzed in central laboratories, according to a report in Clinical Infectious Diseases.

Published
22 August 2018
From
Science Speaks
Why the world may force women to choose: No birth control, no ARVs

A new drug could save 25 000 women living with HIV but could it come at the cost of their babies lives?

Published
22 August 2018
From
Bhekisisa
For Those Born With HIV, Adulthood Is Marked by Successes and Challenges

Children who are born with HIV typically hit standard adult milestones but often struggle with serious life challenges, such as mental health problems and substance use disorders. Outcomes were similar for HIV-positive individuals and HIV-negative but perinatally exposed individuals.

Published
22 August 2018
From
Poz
Vatican makes progress on pushing drug availability for kids with HIV

An initiative to identify and properly treat children living with HIV has gained new momentum as international organizations and pharmaceutical companies respond to a Vatican push to look past profit to doing the right thing.

Published
10 August 2018
From
Crux: Covering all things Catholic
AIDS 2018: The Story is Messy

It's already clear that the story from Amsterdam is that ending epidemic levels of new HIV diagnoses depends on building services and societies that recognize individuals as wonderful, wild, weird, whole people, with more specificity, respect and rigor than ever before. It also depends on activism, nasty women and their male allies, everyone demanding change, refusing to play nice.

Published
26 July 2018
From
AVAC
Pfizer and GSK's HIV/AIDS division, ViiV, prevents children with HIV from getting needed medicine

Despite ViiV pledging in November 2017 that it would expedite the availability of paediatric dolutegravir formulations where these are most critically needed, and despite repeated appeals from MSF and others, almost 18 months after paediatric formulations of dolutegravir were approved for use by the European Medicines Agency, the corporation has started the registration process in only three sub-Saharan African countries

Published
23 July 2018
From
Médecins Sans Frontières (MSF) International
Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1

New pharmacokinetic data show mean exposure of darunavir (brand name Prezista) boosted with cobicistat (available in combination in Rezolsta, Symtuza) to be lower during the second and third trimesters of pregnancy than during 6–12 weeks postpartum. Low darunavir exposure may be associated with an increased risk of treatment failure and an increased risk of HIV-1 transmission to the unborn child.

Published
18 July 2018
From
MHRA
Dolutegravir preconception signal: time is up for shoddy surveillance

The news in May 2018 of a potential risk of neural tube defects in infants born to women taking dolutegravir (DTG) at the time of conception sent shockwaves through the HIV community. But, despite massive global investment, aggressive transition plans – as well as calls for years for more systematic recording of outcomes when women receive ART in pregnancy– few prospective birth registrieshave been established in other settings that can refute or confirm this finding. Meanwhile, women of child-bearing age, whether they intend to become pregnant or not, are being told that they must stick with (or go back to) efavirenz (EFV) – a drug that, before this news, was in the process of being replaced with DTG.

Published
16 July 2018
From
HIV i-Base

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.